Nuvation Bio (NASDAQ:NUVB) received U.S. Food and Drug Administration approval for a supplemental New Drug Application updating efficacy information for IBTROZI (taletrectinib) in TKI-naïve adults with advanced ROS1-positive non-small cell lung cancer.
Bristol Myers Squibb (NYSE:BMY) reported positive two-year results from the Phase 3 POETYK PsA-2 study and its open-label extension, showing continued efficacy and a consistent safety profile for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis.
Indivior Pharmaceuticals (NASDAQ:INDV) declared a contingent special cash dividend of $8.13 per share, with payment dependent on the completion of its pending merger with Supernus Pharmaceuticals.
Aquestive Therapeutics (NASDAQ:AQST) resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for Anaphylm (dibutepinephrine) sublingual film, a treatment candidate for Type I allergic reactions including anaphylaxis.
Aethlon Medical (NASDAQ:AEMD) and North Immunology entered a definitive all-stock merger agreement that will combine the companies around NOR-101, a half-life extended IL-13 x IL-18 bispecific antibody being developed for atopic dermatitis and other immune-mediated diseases.
Sanofi (NASDAQ:SNY) and Cheplapharm announced plans to create a strategic partnership under which Cheplapharm would acquire a portfolio of 20 mature medicines and three manufacturing sites from Sanofi, with Sanofi receiving a 26.4% equity stake in Cheplapharm.
111 (NASDAQ:YI) received an unsolicited, preliminary and non-binding proposal from a buyer group to acquire all outstanding Class A ordinary shares not already owned by the group and take the company private.
Innate Pharma (NASDAQ:IPHA) reported revenue and other income of €5.7 million for the first half of 2026, while posting a net loss of €19.6 million as the biotechnology company adjusted its research and development activities.
IDEXX Laboratories (NASDAQ:IDXX) announced an expansion of its Faecal Dx™ antigen testing platform in the United Kingdom to detect taeniid tapeworms, including Taenia and Echinococcus species, adding another parasite group to its veterinary testing offering.
Sunshine Biopharma (NASDAQ:SBFM) advanced its lead coronavirus PLpro inhibitor into IND-enabling studies after preclinical testing showed antiviral activity against SARS-CoV-2 variants.
Twist Bioscience (NASDAQ:TWST) entered an agreement with Lilly TuneLab, an artificial intelligence and machine learning drug discovery platform created by Eli Lilly (NYSE:LLY), to provide antibody characterization data services.
Adagio Medical (NASDAQ:ADGM) announced the first patient treated in a clinical study evaluating its next-generation vCLAS Ultra Ultra-Low Temperature Ablation system for sustained monomorphic ventricular tachycardia.
